Scientists criticize food manufacturers for massive profits from sales of unhealthy ultraprocessed food

A three-part Lancet series by 43 global nutrition experts, backed by WHO and UNICEF, concludes that ultraprocessed foods (UPFs) are a principal driver of global obesity, chronic disease and premature death and that UPF manufacturers accounted for over half of the $2.9 trillion paid to food-company shareholders from 1962–2021. The papers cite randomized trials showing UPF diets lead to an extra 500–1,000 calories per day, a meta-analysis linking UPFs to a dozen chronic illnesses, and widespread industry tactics—marketing modeled on Big Tobacco, lobbying, funding favorable research—to resist regulation. Authors call for coordinated global action (taxes, front-of-package warnings, restrictions on marketing to children) and note partial successes in jurisdictions such as Chile, Mexico and the UK; the series signals intensifying regulatory, litigation and reputational risk for UPF-centric food and beverage companies even as they expand into emerging markets.

Analysis

A three-part Lancet series authored by 43 global nutrition experts and supported by WHO and UNICEF concludes that ultraprocessed foods (UPFs) are a principal driver of global obesity, multiple chronic diseases and premature death; the papers cite randomized trials showing UPF diets lead to an additional 500–1,000 calories per day and report that 92 of 104 studies found an association between UPFs and higher disease risk. The research also notes that UPF manufacturers accounted for more than 50% of the $2.9 trillion paid to food-company shareholders from 1962–2021, underscoring the sector’s historical cash-generation and shareholder-return profile.

The series documents coordinated industry tactics — marketing modeled on tobacco, political lobbying, funding favorable research — and highlights rapid geographic expansion into South America, Africa, Eastern Europe, China and India as developed markets saturate. Regulatory precedents (soda taxes, front-of-package warnings, marketing restrictions) in Chile, Mexico, the UK and others show partial effectiveness but also indicate an intensifying global policy push led by WHO and UNICEF that raises regulatory, litigation and reputational risk for UPF-centric firms.

Near-term uncertainty remains because critics note much evidence is observational and industry disputes consensus, so the timing and scope of global action are unclear. Investors should therefore treat policy announcements, reformulation costs, and shifts in marketing or geographic mix as primary catalysts that can compress margins and alter growth trajectories for exposed food and beverage companies.

Key Decisions for Investors

• Reduce exposure to companies with a high revenue share from ultraprocessed products or heavy historical shareholder distributions to UPF manufacturers, as taxes, labeling and litigation could compress margins and returns
• Overweight or selectively add exposure to companies with proven minimally processed or healthy-brand portfolios, transparent reformulation plans, and clear governance/lobbying disclosures, as they face lower regulatory and reputational risk
• Monitor regulatory developments in jurisdictions cited by the paper (Chile, Mexico, UK, South Korea, EU) and treat new taxes, front-of-package label rules or marketing bans as immediate negative catalysts for UPF-heavy names
• Use hedges or relative-value trades (for example, short UPF-centric equities versus long diversified or health-focused peers) and avoid initiating material new long positions in exposed companies until managements publish credible mitigation strategies